SCAND1 and prostate carcinoma: To clarify the prognostic values of MZF1 and SCAND1, we next investigated whether MZF1 and SCAND1 high or low expression correlated with survival rates of patients suffering from pancreatic, head and neck, kidney, and prostate cancers.